Your browser doesn't support javascript.
loading
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran, S; O'Sullivan, C C; Elkhanany, A; Anderson, I C; Barve, M; Blau, S; Cherian, M A; Peguero, J A; Goetz, M P; Plourde, P V; Portman, D J; Moore, H C F.
Affiliation
  • Damodaran S; Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston. Electronic address: SDamodaran@mdanderson.org.
  • O'Sullivan CC; Department of Oncology, Mayo Clinic, Rochester.
  • Elkhanany A; Baylor College of Medicine, Duncan Cancer Center - Breast, Houston.
  • Anderson IC; Providence Medical Group, Santa Rosa.
  • Barve M; Mary Crowley Cancer Research, Dallas.
  • Blau S; Oncology Division, Northwest Medical Specialties, PPLC, Puyallup.
  • Cherian MA; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus.
  • Peguero JA; Department of Research, Oncology Consultants PA, Houston.
  • Goetz MP; Department of Oncology, Mayo Clinic, Rochester.
  • Plourde PV; Sermonix Pharmaceuticals, Columbus.
  • Portman DJ; Sermonix Pharmaceuticals, Columbus.
  • Moore HCF; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
Ann Oncol ; 34(12): 1131-1140, 2023 12.
Article in En | MEDLINE | ID: mdl-38072513
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article